评述:"PSCA CAR 工程化 Vδ1 γδ T 细胞用于胰腺癌免疫治疗的疗效与安全性比较"
Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".
FRONTIER PAPERS
Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".
Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer.
PSCA CAR-V 1 T 细胞是 PSCA + PC 的一种强效且安全的治疗方式,其疗效与其他 CAR-T 细胞类型相当,并在安全性和持久性方面具有潜在优势。
An oncolytic system produces oxygen selectively in pancreatic tumor cells to alleviate hypoxia and improve immune activation.
响应性氧气自供给 adv-MCK 级联反应系统联合光动力疗法可改善胰腺癌缺氧微环境并增强抗肿瘤免疫,为胰腺癌提供了一种有前景的替代治疗策略。
Regulation of immunological tolerance by the p53-inhibitor iASPP.
The pancreatic tumor microenvironment of treatment-naïve patients causes a functional shift in γδ T cells, impairing their anti-tumoral defense.
Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer.
The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer.
Secretogranin II serves as a potential prognostic biomarker and correlates with the immune microenvironment in pancreatic neuroendocrine tumors.
这些发现表明,SCG2 是 pNETs 潜在的预后标志物和治疗靶点。它可能通过调节肿瘤免疫微环境参与疾病进展,提示其在预后评估和临床管理中可能发挥作用。
Synergistic Effect of Fecal Microbiota Transplantation, γδT Cell Immunotherapy, and Pembrolizumab in Refractory Advanced Pancreatic Cancer: A Case Rep
本病例提示,FMT 联合γδ T 细胞治疗可能是晚期 PC 的一种有前景的免疫治疗策略。需要进一步研究以验证这些发现。
Integrated bioinformatics analysis identifies PCSK9 as a prognosticator correlated with lipid metabolism in pancreatic adenocarcinoma.
我们的研究确定 PCSK9 是 PAAD 中的一个关键基因。PCSK9 的表达水平在 PAAD 和正常样本之间存在差异。ROC 分析验证了 PCSK9 具有强大的区分 PC 与正常样本的能力。重要的是,PCSK9 在 PC 细胞系和组织中的表达显著升高。此外,PCSK9 在体内和体外均促进肿瘤细胞的迁移和增殖。
MEMBER ACCOUNT
登录成功会直接打开下一页。